Literature DB >> 30302213

New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia.

Xavier Thomas1.   

Abstract

Entities:  

Keywords:  CAR T-cells; acute lymphoblastic leukemia; monoclonal antibodies; prognosis; targeted therapy

Year:  2017        PMID： 30302213      PMCID： PMC6171993          DOI： 10.2217/ijh-2017-0004

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


× No keyword cloud information.
  23 in total

1.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

4.  Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; Dietrich Beelen; Paul Browne; Liisa Volin; Slawomira Kyrcz-Krzemien; Ibrahim Yakoub-Agha; Mahmoud Aljurf; Depei Wu; Mauricette Michallet; Renate Arnold; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-09-29       Impact factor: 9.941

5.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

6.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

7.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

8.  Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.

Authors:  Tobias Herold; Stephanie Schneider; Klaus H Metzeler; Martin Neumann; Luise Hartmann; Kathryn G Roberts; Nikola P Konstandin; Philipp A Greif; Kathrin Bräundl; Bianka Ksienzyk; Natalia Huk; Irene Schneider; Evelyn Zellmeier; Vindi Jurinovic; Ulrich Mansmann; Wolfgang Hiddemann; Charles G Mullighan; Stefan K Bohlander; Karsten Spiekermann; Dieter Hoelzer; Monika Brüggemann; Claudia D Baldus; Martin Dreyling; Nicola Gökbuget
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

9.  Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

Authors:  Sébastien Maury; Sylvie Chevret; Xavier Thomas; Dominik Heim; Thibaut Leguay; Françoise Huguet; Patrice Chevallier; Mathilde Hunault; Nicolas Boissel; Martine Escoffre-Barbe; Urs Hess; Norbert Vey; Jean-Michel Pignon; Thorsten Braun; Jean-Pierre Marolleau; Jean-Yves Cahn; Yves Chalandon; Véronique Lhéritier; Kheira Beldjord; Marie C Béné; Norbert Ifrah; Hervé Dombret
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

10.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Authors:  E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.